Potent, selective and irreversible inhibitor of MAG lipase (IC50=8nM vs 4µM for FAAH). JZL-184-treated mice displayed a number of CB1-dependent behavioral effects including analgesia, hypothermia and hypomotility as well as increased levels of 2-arachidonoylglycerol in the brain ( approx. 8-fold, with no effect on anandamide levels). JZL-184 produces a rapid and sustained blockade of brain 2-AG hydrolase activity in mice. It blocks neuropathic pain and enhances retrograde endocannabinoid signaling.
Product Specification
| Alternative Name: | 4-Nitrophenyl-4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate |
| |
| Formula: | C27H24N2O9 |
| |
| MW: | 520.5 |
| |
| Source: | Synthetic. |
| |
| CAS: | 1101854-58-3 |
| |
| Purity: | ≥98% (TLC) |
| |
| Identity: | Determined by NMR. |
| |
| Appearance: | Off-white solid. |
| |
| Solubility: | Soluble in DMSO (10mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | Ambient |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling: B. Pan, et al.; J. Pharmacol. Exp. Ther.
331, 591 (2009),
Abstract;
Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain: S.G. Kinsey, et al.; J. Pharmacol. Exp. Ther.
330, 902 (2009),
Abstract;
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects: J.Z. Long, et al.; Nat. Chem. Biol.
5, 37 (2009),
Abstract;
